Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (137)	8/16/1998 7:45:00 PM
From: Lel H	Read Replies (2) \| Respond to of 626

Hi Miljenko. I hope you had an enjoyable time across the "big pond". I didn't realize that the Iloperidone trial was going to be so complicated. When I spoke to Bob Farrell, the CFO of Titan, he only mentioned that there would be two dosing schedules tested, which would enroll something like 3500 patients and cost well in excess of $100 million. But it has been some time since I last made contact with Titan. But it would also be good if Ilo could be compared directly with its likely competitors. The market is beating down Titan these days, and at this point I doubt that the announcement of phase III trials will have any effect on the stock price. Unless they report something really remarkable for their cancer vaccines, it may a long road back to $5 from current levels. It's nice to hear from you. Best wishes. Lel